Table 4 Regression models for combined dataset
Drug group | R2 | Needs indicator | Beta coefficient | % explained |
|---|---|---|---|---|
Statins | .249 | CHD HES rate | .350 | 14.7 |
| Â | Â | % patients aged >75 | -.240 | 4.2 |
| Â | Â | Ethnicity | -.233 | 3.1 |
|  |  | % patients aged 55–74 | .199 | 2.9 |
Aspirin | .512 | CHD HES rate | .579 | 32.9 |
| Â | Â | LISI score | -.261 | 10.4 |
| Â | Â | % patients aged >75 | .347 | 8.2 |
ACE inhibitors | .316 | Ethnicity | -.395 | 25.3 |
| Â | Â | % patients aged >75 | -.170 | 3.4 |
|  |  | % patients aged 55–74 | .248 | 2.9 |
Beta-blockers | .271 | CHD HES rate | .411 | 19.7 |
|  |  | % patients aged 55–74 | .274 | 7.4 |
Bendrofluazide | .241 | LISI score | -.261 | 13.1 |
| Â | Â | CHD HES rate | .171 | 6.6 |
|  |  | % patients aged 55–74 | .274 | 4.4 |
All CHD drugs | .454 | LISI score | -.303 | 22.7 |
| Â | Â | CHD HES rate | .461 | 20.0 |
|  |  | % patients aged 55–74 | .242 | 2.7 |